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Background: Patients may react in different ways to drugs and genetic factors have to be 
considered when observing variability in drug responses.1 Drugs acting as agonists for the 
alpha 2 adrenoceptor (formerly called α2 adrenergic receptor), such as xylazine, detomidine, 
medetomidine, or romifidine are regularly used for sedation, premedication and analgesia in 
veterinary medicine.2,3 Three genes encode for separate subtypes of alpha 2 adrenoceptors, 
ADRA2A, ADRA2B, and ADRA2C.4 Alpha 2 adrenoceptors modulate the regulation of blood 
pressure, renal function, insulin release, cognition, memory and behaviour.5 Adra2a mutant 
mice (𝛼𝛼2AD79N) are resistant to sedation with dexmedetomidine.6,7 
Own analysis: A 9-year old Swiss Warmblood horse was presented due to anorexia. Since the 
horse was highly aggressive, clinical examination was only deemed possible under general 
anaesthesia. Therefore, tiletamine-zolazepam (2mg/kg) and medetomidine (0.04 mg/kg) were 
administered intramuscularly by blowpipe darting. While the drug-related side effects such as 
sweating, polyuria, tremor and ataxia were observed, the sedative effect remained absent. 
Therefore 35 minutes later a second dart containing tiletamine-zolazepam (1 mg/kg) and 
medetomidine (0.04 mg/kg) was shot, again without noticeable sedative effects. We 
sequenced the genome of this horse at 28x coverage as described (study accession 
PRJEB14779, sample accession SAMEA104357351).8 We called private variants with respect 
to 80 genomes from other horses of different horse breeds (Table S1). This analysis yielded 
26,416 private variants, 222 of them predicted to be protein-changing (Table S2). During this 
analysis we recognized that ADRA2A, ADRA2B and ADRA2C contain gaps and/or are not 
correctly annotated in the current EquCab 2 assembly. Therefore, our automated 
bioinformatics pipeline for variant detection would not necessarily have detected all possible 
variants within these genes. Based on preliminary data from the ongoing efforts to produce an 
EquCab 3 assembly we designed PCR primers for the amplification of the entire ADRA2A, 
ADRA2B and ADRA2C genes (Table S3). We Sanger sequenced these genes from the 
medetomidine-resistant horse and a control horse and deposited curated reference sequences 
for these 3 genes in the European Nucleotide Archive (accessions LT935786 – LT935788). 
We did not detect any protein-changing variant in the medetomidine-resistant horse. 
Comments: Coding variants in ADRA2A, ADRA2B and ADRA2C can be excluded for the 
observed insensitivity to medetomidine in a Swiss Warmblood horse. We provide new genomic 
reference sequences for these three genes. 
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